{"version":"1.0","type":"link","title":"First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.","author_name":"Shitara K 외","author_url":"https://prs-insight.online/author/Shitara%20K","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167600","thumbnail_width":1200,"thumbnail_height":630}